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Abstract
Background: Several complications of diabetes mellitus (DM) e.g. nephropathy (DN) have been linked to oxidative 
stress. Ozone, by means of oxidative preconditioning, may exert its protective effects on DN.
Aim: The aim of the present work is to study the possible role of ozone therapy in ameliorating oxidative stress and 
inducing renal antioxidant defence in streptozotocin (STZ)-induced diabetic rats.
Methods: Six groups (n = 10) of male Sprague Dawley rats were used as follows: Group C: Control group. Group O: 
Ozone group, in which animals received ozone intraperitoneally (i.p.) (1.1 mg/kg). Group D: Diabetic group, in which 
DM was induced by single i.p. injections of streptozotocin (STZ). Group DI: Similar to group D but animals also received 
subcutaneous (SC) insulin (0.75 IU/100 gm BW.). Group DO: In which diabetic rats received the same dose of ozone, 48 
h after induction of diabetes. Group DIO, in which diabetic rats received the same doses of insulin and ozone, 
respectively. All animals received daily treatment for six weeks. At the end of the study period (6 weeks), blood pressure, 
blood glycosylated hemoglobin (HbA1c), serum creatinine, blood urea nitrogen (BUN), kidney tissue levels of 
superoxide dismutase (SOD), catalase (CAT), glutathione peroxide (GPx), aldose reductase (AR) activities and 
malondialdehyde (MDA) concentration were measured.
Results: Induction of DM in rats significantly elevated blood pressure, HbA1c, BUN, creatinine and renal tissue levels of 
MDA and AR while significantly reducing SOD, CAT and GPx activities. Either Insulin or ozone therapy significantly 
reversed the effects of DM on all parameters; in combination (DIO group), they caused significant improvements in all 
parameters in comparison to each alone.
Conclusions: Ozone administration in conjunction with insulin in DM rats reduces oxidative stress markers and 
improves renal antioxidant enzyme activity which highlights its potential uses in the regimen for treatment of diabetic 
patients.
Background
A high percentage of type I and II diabetic patients even-
tually develop diabetic nephropathy (DN) that may prog-
ress to end-stage renal disease (ESRD) [1]. Type I diabetes
mellitus (DM) usually manifests early in life. So, ESRD
may develop at a relatively younger age, producing an
additional burden for patients and health services [2].
The structural injury in DN develops before the clinical
and laboratory abnormalities such as hypertension, albu-
minuria or reduction of the glomerular filtration rate
[3,4]. Thus, waiting for clinical or laboratory manifesta-
tions of renal disease before starting treatment may hin-
der efforts to prevent ESRD. Several pathways involving
hemodynamic and metabolic factors have been impli-
cated in the pathogenesis of DN including oxidative stress
[5], activation of protein kinase C [6], increased forma-
tion of advanced glycation end products [7] and polyol-
hexosamine pathway flux [8]. The excessive production
of reactive oxygen species (ROS) has been suggested as a
common outcome from all these pathways leading to
increased oxidative damage at the level of lipid peroxida-
tion [9] and culminating in DN in association with DM
[10]. Thus, any treatment which is able to stabilize oxygen
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metabolism and modulate oxidative stress would help to
delay the onset of DN in diabetes mellitus.
Many controlled trials have examined the validity of
using ozone as a therapeutic agent for the treatment of
several disorders [11]. Ozone therapy stimulates the anti-
oxidant response in cardiomyopathy patients [12] and
increase oxygen unloading capacity of hemoglobin in dia-
betic patients [13]. Ozone administration also been
shown to exert a protective effect against liver damage
induced by carbon tetrachloride and renal ischemic-rep-
erfusion injury by an oxidative preconditioning mecha-
nism that stimulates antioxidant endogenous systems and
modulates nitric oxide (NO) production [14]. The main
purpose of this work is to determine the role of ozone
administration in ameliorating oxidative stress in STZ-
induced DN in diabetic rats so as to establish its potential
use in the strategy for the treatment of diabetic patients.
Methods
Experimental animals and groups
This study was carried out on 60 male Sprague-Dawley
rats weighing between 150 and 200 g obtained from the
National Research Centre, Cairo, Egypt. The animals
were divided into six equal groups. Animals were fed with
a standard laboratory chow and water, ad libitum, and
housed in the animal house of Menoufiya Faculty of Med-
icine, Egypt with a 12:12-h light/dark cycle. The study
groups were as follows: Group C: Control group, injected
(i.p.) with citrate buffer (0.1 M, pH 4.5). Group O: Ozone
group, given ozone treatment i.p. at a dose of 1.1 mg/kg.
This dose of ozone has been shown to achieve oxidative
preconditioning without appreciable toxicity [15]. Group
D: Untreated diabetic group. DM was induced by single
i.p. injections of streptozotocin (STZ). Group DI: Rats
made diabetic as in group D were given mixtard insulin
30 (40 IU/ml) subcutaneous (Novo Nordisk, Denmark) at
a dose of 0.75 IU/100 gm BW once daily in 0.75 ml vol-
umes [16]. Group DO: Diabetic rats received the same
dose of ozone as group O, 48 h after induction of diabe-
tes. Group DIO: Diabetic rats received the same doses of
insulin and ozone as in groups DI and DO, respectively.
Groups C, D and DO also received SC injections of 0.75
ml saline daily, while groups C, D and DI were injected
i.p. with oxygen (the vehicle for O3) in the same gas vol-
ume as the ozone/oxygen mixture. All animals were
treated daily for six weeks.
Induction of diabetes and ozone preparation
DM was induced with single IP injections of STZ (45 mg/
kg) in freshly prepared citrate buffer (0.1 M, pH 4.5)
(Sigma Chemical Company, USA), while control rats
were injected with vehicle buffer only. DM was verified by
measuring blood glucose in tail nick blood samples. Rats
with non fasting blood glucose levels of ≥20 mmol/L after
48 h of STZ injection were considered diabetic [17]. The
study duration was 6 weeks, a period which has been
shown to induce detectable diabetic complications in the
kidney [18,19]. Ozone was generated with ozonator
equipment (Ozone Longevity Resources Dwyermade,
Canada). The ozone concentration in the O3/O2 mixture
was 50 μg/ml and was i.p. administered. Ozone was
obtained from medical grade oxygen and was used imme-
diately upon generation and represented only about 3% of
the O3/O2 gas mixture. The ozone concentration was
measured using a UV spectrophotometer at 254 nm. The
ozone given to each animal was adjusted to a final dose of
1.1 mg/kg BW [20].
Measurement of blood pressure
At the end of the experimental period, blood pressure
was measured using the rat-tail sphygmomanometer
technique (Harvard Apparatus Ltd., England) [21]. Sys-
tolic blood pressure (SBP) and mean arterial blood pres-
sure were estimated from recorded graphs. Diastolic
blood pressure (DBP) was calculated from the expression
- Mean pressure equals diastolic pressure plus one third
pulse pressure [22].
Blood and tissue sampling
At the end of the 6th week, retro-orbital blood samples
were obtained under anaesthesia (sodium thiopental at
40 mg/kg IP Bio-chem, Austria) [23]. The samples were
divided into two parts. The first part was allowed to clot
for 20 min, and then centrifuged at 14,000 rpm for 10 min
to obtain serum used for the determination of BUN and
creatinine levels. The other part was collected in tubes
containing potassium oxalate and sodium fluoride and
used to measure plasma glucose and HbA1c. The animals
were killed by decapitation; kidneys were dissected out,
cut into small pieces and homogenized in ice-cold 50 mM
Tris, 1.0 mM EDTA, pH 8.0, with 10 mM 4-(2 amino-
ethyl) benzenesulfonyl fluoride (AEBSF), 2 mM dithio-
threitol, 5 mM leupeptin, 2 mM pepstatin, using an Omni
tissue homogenizer (Omni international, Gainesville,
VA). The extracts were centrifuged at 14,000 rpm for 30
min at 4°C. The supernatant was stored at -80°C for vari-
ous assays.
Biochemical analyses
Serum BUN was determined by an enzymatic colorimet-
ric method using a commercial kit (Boehringer Man-
heim, Germany). This method is based on urease (urea
amidohydrolase)/glutamate dehydrogenase coupled reac-
tions and uses a two-point fixed-time kinetic scheme for
monitoring the rate of consumption of NADH at 340 nm
[24]. Serum creatinine was determined by the Jaffe reac-
tion in which creatinine reacts with picrate ion in an alka-
line medium to yield an orange red complex which wasMorsy et al. Diabetology & Metabolic Syndrome 2010, 2:29
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measured at 490 nm [25]. Plasma glucose was determined
using the glucose oxidase method [26]. Addition of per-
oxidase and a chromogenic oxygen acceptor results in the
formation of a coloured compound that can be measured
at 500 nm (Life Scan, CA, USA). HbA1c was determined
according to the chemical separation and colorimetric
method based on the phenol sulphuric acid reaction of
carbohydrates. Hemolyzates were treated with 1 mol/l
oxalic acid in 2 mol/l HCl for 4 h at 100°C; the protein
was precipitated with trichloroacetic acid, and the free
sugars and hydroxymethyl furfural in the supernatant
were treated with phenol and sulphuric acid to form the
colour [27]. MDA concentration was measured in tissue
homogenates after precipitation of protein with trichlo-
roacetic acid. Thiobarbituric acid (TBA) reacts with
MDA to form TBA reactive product, which was mea-
sured at 532 nm spectrophotometrically. An MDA solu-
tion freshly made by the hydrolysis of 1,1,3,3-
tetramethoxy propane was used as standard [28]. The
results were expressed as nmol of MDA per mg protein.
Enzyme Activity Assays
SOD (EC 1.15.1.1) activity in kidney homogenates was
assayed following the method developed by Nishikimi et
al. [29] as modified by Kakkar et al. [30]. Five μg protein
was mixed with sodium pyrophosphate buffer, phenazine
methosulphate (PMT) and nitro blue tetrazolium (NBT).
The reaction was started by the addition of NADH. The
reaction mixture was then incubated for 90 seconds at
30°C and stopped by the addition of 1 ml of glacial acetic
acid. The absorbance of the chromogen formed was mea-
sured at 560 nm. One unit of SOD activity was defined as
the enzyme concentration required to inhibit chromogen
production by 50% in one minute under the assay condi-
tions.  CAT (EC 1.11.1.6) activity was measured in
homogenates by the method of Bonaventura et al. [31].
Five μg protein from the homogenate was mixed with 2
ml of 7.5 mM H2O2 and a time scan was performed for 10
min at 240 nm at 25°C. One unit of CAT activity was
defined as the amount of enzyme decomposing 1 μmol of
H2O2 per minute. GPx (EC 1.11.1.9) activity was assayed
by Paglia and Valentine's method [32], using H2O2 and
NADPH as substrates. The conversion of NADPH to
NADP+ was followed by recording the changes in absorp-
tion intensity at 340 nm (Ransel kit, Randox, UK), and
one unit was expressed as 1 nM of NADPH consumed
per minute/mg tissue. AR activity was determined in a
reaction mixture containing sodium phosphate buffer
(0.1 M, pH 6.2), 150 mM NADPH, 10 mM DL-glyceralde-
hyde, and the enzyme solution in a total volume of 1 ml.
The reaction was started by the addition of enzyme and
activity was measured by estimating NADPH oxidation
as a decrease in absorbance at 340 nm. Assays were car-
ried out at room temperature with appropriate blanks
subtracted from each reaction to correct for nonspecific
oxidation of NADPH during the measurement. One unit
of enzyme activity was defined as the amount of enzyme
catalyzing the oxidation of 1 mM of NADPH/min/mg tis-
sue under the assay conditions [33].
Statistical analysis
All data were expressed as means ± SEM. The means for
the different groups were compared using Kruskal Wallis
one-way ANOVA (one-way analysis of variance), fol-
lowed by Post Hoc test. The level of significance for all
comparisons was set at P < 0.05.
Results
Blood pressure measurements
There were significant increases in SBP and DBP of dia-
betic rats when compared to control group (C). However,
treatment of diabetic rats with either insulin (group DI)
or ozone (group DO) significantly reduced both SBP and
DBP values when compared to group D (P < 0.01). Fur-
thermore, combined treatment with insulin and ozone in
group DIO significantly lowered both SBP and DBP
b l o o d  p r e s s u r e  r e l a t i v e  t o  D ,  D I  a n d  D O  g r o u p s  ( P  <
0.001) (Table 1).
Glycosylated hemoglobin
HbA1c levels were significantly higher in diabetic animals
when compared with controls (group C). Insulin treat-
ment significantly reduced HbA1c in diabetic rats (group
DI) relative to untreated diabetic animals (group D) (P <
0.001). Ozone treatment in diabetic rats (DO) reduced
HbA1c significantly; while concomitant treatment with
insulin and ozone in group DIO reduced HbA1c levels fur-
ther, restoring them to near normal values (Table 1).
Serum BUN and creatinine levels
Induction of diabetes in group D resulted in significant
elevation of both BUN and creatinine when compared
with control levels (C). Treatment of diabetic animals
with insulin alone affected neither BUN nor creatinine
significantly, while ozone administration alone signifi-
cantly reduced both BUN and creatinine when compared
to the diabetic group (D). Combined treatment with insu-
lin and ozone in group DIO resulted in significant reduc-
tions of BUN and creatinine relative to either D or DI or
DO groups, restoring them to near normal levels (Table
1).
Kidney tissue SOD, CAT and GPx activities
Whereas ozone therapy in control rats produced no sig-
nificant changes in kidney tissue SOD, CAT and GPx
activity levels, induction of diabetes in group D produced
significant decreases in the activity levels of the threeMorsy et al. Diabetology & Metabolic Syndrome 2010, 2:29
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enzymes when compared with control rats (group C).
Insulin and ozone treatment in groups DI and DO caused
significant increases in kidney homogenate activity of
SOD, CAT and GPx when compared with untreated dia-
betic rats (D). Concomitant administration of both insu-
lin and ozone in diabetic rats produced significant
increases in all measured antioxidant enzyme activities
relative to their corresponding values in D, DI and DO
groups, restoring them to near normal levels (Figure 1).
Kidney tissue MDA concentration and AR activity
Induction of diabetes in group D significantly increased
kidney tissue levels of MDA and AR enzyme activities
when compared with the control group (C). Insulin treat-
ment (DI) and ozone administration (DO) in diabetic rats
independently produced significant decreases in both
MDA and AR activity when compared with group (D).
Concomitant administration of insulin and ozone
brought MDA and AR activity levels to near normal levels
by significantly greater reductions of activity levels rela-
tive to D, DI or DO groups (figure 2).
Discussion
Oxidative stress in DM accelerates the development of
diabetic micro- and macro-vascular complications
through poorly understood mechanisms [34]. Hyperten-
sion, as a vascular complication of DM, is frequently seen
in Type I DM and many factors are involved in its patho-
genesis including the availability of nitric oxide, increased
production of ROS and alterations in the renin-angio-
tensin system as well as dyslipidaemia [35]. There are evi-
dences that, the formation of ROS is a direct consequence
of hyperglycemia and is associated with the vascular
complications seen in diabetic patients [2,36]. Induction
of diabetes in the present study causes significant eleva-
tions of both SBP and DBP when compared to the control
group. Either insulin (Group DI) or ozone (Group DO)
treatment independently resulted in significant reduc-
tions in both SBP and DBP. This could be explained by
the vasodilator effect of both agents with their ability to
induce endothelial cell NO production [14,37].
Development of DN in the present study was con-
firmed by significant elevations of serum creatinine and
BUN as well as the development of hypertension, as ear-
lier reported by Knoll et al. [18]. The significant reduction
of renal antioxidant enzyme activities with significant ele-
vation of MDA and AR may be related to a higher level of
oxidative stress in diabetic rats. Oxidative stress may be
responsible for several complications of DM, including
nephropathy, retinopathy and atherosclerotic vascular
diseases due to overproduction of ROS with subsequent
lipid peroxidation [38,39]. Hyperglycaemia reduces the
synthesis and activities of a number of antioxidant
enzymes including SOD and GPx, presumably by glyca-
tion [5]. It is well established that diabetic patients have a
lower antioxidant defences, enzymatic (SOD, CAT, GPx)
and non-enzymatic (vitamin C, E or A, free radical scav-
engers) [5]. The role of oxidative stress in the pathogene-
sis of DN is not only through overproduction of ROS but
also through the reduction of antioxidant enzyme activi-
Table 1: Effect of six weeks ozone treatment on different parameters in STZ induced diabetes in rats.
Group SBP (mmHg) DBP (mmHg) (Hb A1c %) BUN (mmol/L) Creatinine 
(μmol/L)
C 106.1 ± 5.9 88.3 ± 5.6 7.4 ± 1.36 5.72 ± 0.25 45.9 ± 2.6
O 101 ± 4.8 79.5 ± 2.1 7.1 ± 1.25 4.26 ± 0.82 36.2 ± 4.4
D 165.4 ± 6.7 * ° 127.3 ± 4.2 * ° 16.1 ± 1.47 * ° 35.15 ± 4.35 * ° 184.7 ± 1.8 * °
DI 109.5 ± 3.6 ° # 100.2 ± 4.1 ° # 8.3 ± 0.38 ° # 27.50 ± 5.79 * ° 165.3 ± 11.4 * °
DO 102.5 ± 5.2 ° # 97.3 ± 5.3 ° # 8.9 ± 1.02 ° # 11.35 ± 5.37 * ° # ˆ 92.8 ± 15.1 * ° #
DOI 87.8 ± 6.5 # ˆ ¥ 78.9 ± 3.2 # ˆ ¥ 7.3 ± 0.24 # ˆ ¥ 5.81 ± 0.73 # ˆ ¥ 47.7 ± 0.88 # ˆ ¥
Effect of treatment with ozone on systolic (SBP), diastolic blood pressures (CBP), glycosylated Hb (Hb A1c), serum creatinine and blood urea 
nitrogen (BUN) (Means ± SE) in control and experimental groups of rats (n = 10).
* Significant change from the corresponding values in Non-diabetes control group.
° Significant change from the corresponding values in Non-diabetes ozone-control group.
# Significant change from the corresponding values in diabetes control group.
ˆ Significant change from the corresponding values in diabetes insulin treated group.
¥ Significant change from the corresponding values in diabetes ozone treated group.Morsy et al. Diabetology & Metabolic Syndrome 2010, 2:29
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ties, auto-oxidation of glucose, impaired glutathione
metabolism, formation of lipid peroxides and non-enzy-
matic protein glycosylation [40,41]. Oxidative stress may
also induce the formation of angiotensin converting
enzyme, protein kinase C and mitogen-activated protein
kinase (MAPK) activation that help in the aggravation of
DN in diabetic patients [42].
The efficacy of ozone therapy in DM has been attrib-
uted to its hypoglycemic effect, induction of antioxidant
enzyme activities [33,43] and control of their expression
[20,44]. The significant reduction of HbA1c, kidney tissue
Figure 1 The effects of ozone on renal SOD, GPx and CAT activities in diabetic nephropathy in rats. The figure shows a) SOD, b) CAT, c) GPx 
activities in kidney tissues homogenate in the different studied groups (n = 10). C = control, O = ozone treated, D = diabetes mellitus, DI = diabetes+in-
sulin, DO = diabetes+ozone, DOI = diabetes+ozone+insulin. (*) significant change from normal control group (p < 0.01). (ˆ) significant change from 
ozone control group (p < 0.01). (#) significant change from diabetic group (p < 0.01). ($) significant change from to diabetic insulin group (p < 0.01). 
(¥) significant change from diabetic insulin group (p < 0.01).
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MDA and AR levels with significant elevation of kidney
tissue SOD, CAT and GPx activities by both ozone and
insulin treatment may be explained by their hypoglyce-
mic effect with subsequent reduction of metabolic com-
plications. This view is supported by Rodriguez et al. [12]
who found that controlling hyperglycemia in diabetic
patients with insulin or other hypoglycemic agent
reduces oxidative stress-induced DN complication in dia-
betes patients. Another possible mechanism could be
through ozone-induced NO synthase expression at the
level of the renal vascular endothelium resulting in arteri-
olar vasodilatation which prevents the development of
DN [45]. Furthermore, ozone has been shown to enhance
antioxidant endogenous systems by means of oxidative
preconditioning and adaptive mechanisms which reduce
vascular complications in diabetic patients [46]. These
findings support our hypothesis that ozone has a renal
protective role against oxidative damage in diabetes mel-
litus.
The antioxidant-prooxidant balance, associated with
the regulatory effects of ozone on AR activity represents
another interesting action of this complementary thera-
peutic approach. Aldose reductase is a key enzyme in the
polyol pathway and its inhibitors have been used as thera-
peutic drugs linked to the enhancement of NO produc-
tion or release [47]. Ozone may also protect against the
imbalance in NO/ROS by preventing NO depletion and
improving NO-mediated vasodilatation in diabetic rats to
r e s t o r e  b l o o d  p r e s s u r e  t o  n o r m a l  v a l u e s  [ 4 3 ] .  A n o t h e r
explanation is that ozone treatment decreases the over-
production of ROS by the mitochondrial electron trans-
port chain in diabetics, thus inhibiting the activation of
the polyol pathway and the increasing in the concentra-
tion of angiotesin enzyme activity [48]. Finally, Ozone
could also induce SOD activity through stimulation of the
SOD gene expression [47].
Both insulin and ozone may act synergistically to
reduce HbA1c level, blood pressure and ROS production
while stimulating antioxidant enzymatic activities to the
control levels. Both of them independently exert hypogly-
cemic effects [33,43]. In addition, ozone enhances antiox-
idant enzyme activity and reduces overproduction of
ROS which together act to protect cell membranes [12].
Also ozone treatment partially reduce the imbalance
between the generation of ROS and scavenging enzyme
activity [49], while insulin may stimulate glucose trans-
porters gene expression at the cellular level to control the
hyperglycemic complications of diabetes [50]. Also, insu-
lin may correct the deleterious effects of hyperglycemia at
the cellular level of the GPx by increasing the level of
nuclear factor kappa B [51]. Thus both insulin and ozone
administration protect diabetic animals from the deterio-
ration of DN.
Conclusions
This study explored the possible mechanisms by which
ozone may improve oxidative stress levels and renal anti-
oxidant system in experimental diabetic rats. So ozone
therapy may be considered as an adjuvant to insulin in
the treatment of diabetes to prevent or alleviate diabetes
induced nephropathy. This opens the way for long-term
studies to confirm the beneficial effects of ozone admin-
istration in diabetic animal models.
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